Industry news6Filtration+Separation May 2008

Pall Corp unveils Technical Innovation Centre in China Pall Corporation has unveiled its first Technical Innovation Centre in Shanghai, China. The Centre, which incorporates a filtration validation lab, provides comprehensive filtration technology support for the Chinese biopharmaceuticals industry, one of the fast growing sectors of the country’s economy.

According to Pall the centre is the latest strategic addition to Pall’s global capabilities for the Asia-Pa-cific biopharmaceuticals market.The facility houses, an advanced filtration validation lab, which is certified to ISO9001, ISO14001 and OSHAS 18001 standards. The lab will help Pall customers meet the requirements of the new Chinese Good Manufacturing Practices (GMPs) now in development, under which significantly increased regulatory guidelines are expected. The centre represents the eleventh filtration validation lab in Pall’s worldwide customer support network.

“We were receiving a growing stream of requests for validation assistance from our life sciences customers, even while the lab was still under construction,” said Kevin Liu Hai, vice president of Pall China Life Sciences. “The need for a world-class filtration validation lab in the Chinese

market is urgent. Our strategy is to deliver easily accessible, dependable, cost effective services and products to our life sciences customers in China to facilitate superior product development and accelerated growth.”

The centre opening activities began on 28 March with a full-

day seminar on pharmaceutical regulation and sterilising filtration validation, held at the Dongjiao Hotel in Shanghai.The seminar, for key life sciences customers, industry leaders and regulators, was led by Jerold Martin, senior vice president, Scientific Affairs, Pall BioPharmaceuticals, and Larry

Scheer, senior product manager, Pall BioPharmaceuticals.

Special opening events continued the following day with a tour of the Tech Centre lab and press conference for customers, industry officials and government representatives.

www.pall.com

Pall Corporation’s Technical Innovation Centre for life sciences, in Shanghai, China.

Siemens’ membrane bioreactor for use inwater projects in Australia and ItalySiemens Water Technologies has been awarded a US$3.6 million contract by the Gippsland Water Factory Alliance (GWFA). Siemens will supply membranes and associated core system components for a membrane bioreactor (MBR) system as part of the new water factory project in the Gippsland region of Victoria, Australia.

The MBR will treat up to 35 million litres per day (MLD) of domestic and industrial wastewater

and will provide the feed for the reverse osmosis system to produce approximately 8 MLD of Class A recycled water for use by local industry. The project is scheduled for completion in late 2008.

The Gippsland Water Factory will reportedly be the first of its kind in Australia. According to Siemens, the project will also help to eliminate the odour problem generated by the open channel section of the Regional Outfall Sewer (ROS), the area’s

main wastewater transportation system.

David Evans, spokesperson for the Gippsland Water Factory, commented: “What this means is that annually, around three gigalitres of Gippsland’s potable water resources will be freed up for other purposes, such as drinking water supplies and environmental flows for our region’s rivers and creeks. This is the equivalent to filling around 1200 olympic-size swimming pools each year.”

Siemens Water Technologies will also supply its pre-treatment to a MBR system to Mediterranea delle Acque’s new wastewater treatment plant (WWTP) in Santa Margherita Ligure and Portofino, Italy.

Housed partially underground, the plant will benefit the coastal villages’ fishing and tourism industries by producing, what Siemens says, will be high-quality effluent that can be used for a variety of reuse purposes.

www.water.siemens.com

fs4504_pg4_11.indd 6fs4504_pg4_11.indd 6 25/04/2008 16:02:0525/04/2008 16:02:05